Core Insights - The company reported a 5.4% organic constant currency sales growth in Q4 2025, marking the fifth consecutive year of mid-single-digit growth or above [2][15][37] - The U.S. business grew by 5.7%, driven by new product momentum and strong robotic sales, while international sales increased by 5% [2][16] - The company is undergoing a significant transformation of its U.S. sales force, aiming for a dedicated and specialized team to enhance productivity and growth [6][8][72] Financial Performance - For the fiscal year 2025, the company achieved net sales of $2.244 billion, a 10.9% increase on a reported basis, and an adjusted EPS of $2.42, up 4.8% year-over-year [15][16][17] - Free cash flow for the year was $1.172 billion, growing over 11% year-over-year, marking the third consecutive year of high single-digit free cash flow growth [19][20] - The adjusted gross margin was reported at 72.4%, higher than the previous year, while the adjusted operating margin was 29.1% [18][19] Strategic Initiatives - The company is focusing on three key strategic priorities: people and culture, operational excellence, and innovation and diversification [8][10][11] - A significant emphasis is placed on enhancing the U.S. sales channel to drive consistent growth, with expectations for the majority of the transition to be completed by 2027 [6][8][72] - The introduction of new products, including the "magnificent seven" platform, is expected to change the standard of care and drive future growth [11][12][72] Market Outlook - The company anticipates organic constant currency revenue growth for 2026 in the low single-digit range (1% to 3%) and adjusted EPS of $8.30 to $8.45 [7][20] - The guidance reflects potential disruptions from the U.S. sales force transition, ongoing international market evolution, and pricing erosion [20][21] - The company expects to prioritize returning capital to shareholders through buybacks, with a plan for up to $1.5 billion in buybacks approved by the board [76]

Financial Data and Key Metrics Changes - The company reported a 2.8% organic constant currency sales growth for Q2 2025, despite an 80 basis point headwind from selling days [8][24] - Adjusted earnings per share (EPS) increased to $2.07, up 3% year-over-year, despite dilution from the Paragon 28 acquisition [24][30] - Full year organic constant currency revenue growth expectations were updated to a range of 3.5% to 4.5%, down from the previous 3% to 5% range [10][32] Business Line Data and Key Metrics Changes - The US hips business grew by 5.2% year-over-year, while US knees saw a sequential increase of 150 basis points, growing 1.7% [9][26] - The Surgical and Sports Medicine (SET) segment reported nearly 5% growth, marking the seventh consecutive quarter of mid-single-digit growth [9][28] - Technology and Data, Bone Cement, and Surgical segments declined by 2.2% due to difficult comparisons from the prior year [29] Market Data and Key Metrics Changes - International organic revenue grew by 3.4%, with global hips increasing by 4% and US hips growing by 5.2% [26] - The company noted strong early adoption of new products, particularly in the US market, contributing to growth [19][20] Company Strategy and Development Direction - The company is focusing on three strategic priorities: people and culture, operational excellence, and innovation and diversification [7][12] - The acquisition of Monogram Technologies aims to enhance the company's capabilities in robotic surgery, with expectations for revenue growth starting in 2027 [13][14] - The company is committed to diversifying into higher growth segments through disciplined mergers and acquisitions [14][68] Management's Comments on Operating Environment and Future Outlook - Management expressed high confidence in the second half of 2025, driven by new product launches and improved operational efficiency [10][11] - The company anticipates a strong growth acceleration in Q3, with expectations of organic growth around 6% [45][76] - Management noted that the orthopedic market remains healthy, with no signs of slowing down [50][53] Other Important Information - The company has reduced its expected tariff impact for 2025 to approximately $40 million, down from earlier estimates of $60 to $80 million [34][85] - Adjusted gross margin was reported at 72.3%, higher than the previous year, due to favorable product mix [30] Q&A Session Summary Question: Can you elaborate on the updated organic sales growth guidance? - Management highlighted confidence in the second half due to the absence of selling day headwinds and favorable comparisons from the previous year [41][42] Question: What are the current trends in the orthopedic market? - Management noted that the orthopedic market remains healthy, with strong volumes and pricing trends [50][52] Question: Can you discuss the Monogram acquisition and its implications? - Management expressed high confidence in the regulatory pathway for Monogram and its potential to disrupt the market with autonomous capabilities [90][91] Question: How do you see knee growth evolving? - Management indicated that recent commercial investments and new product introductions are expected to sustain growth in the knee segment [99][100]

Financial Data and Key Metrics Changes - The company reported net sales of $1.909 billion, an increase of 1.1% on a reported basis and 2.3% excluding foreign currency impact [27] - Adjusted earnings per share (EPS) was $1.81, down from $1.94 in the prior year [33] - Free cash flow generated was $279 million, representing robust growth compared to the prior year [34] - Adjusted gross margin was 71.5% and adjusted operating margin was 26.2%, both lower than the prior year but in line with expectations [33] Business Line Data and Key Metrics Changes - U.S. hips sales grew nearly 4%, while U.S. knees grew only 0.2% [7][30] - The U.S. SET (Surgical Equipment and Technology) business grew by 4.9%, marking the sixth consecutive quarter of at least mid-single-digit growth [31] - International sales grew 3.7%, driven by mid-single-digit growth in knees and high-single-digit growth in SET [28] Market Data and Key Metrics Changes - The U.S. market showed a notable performance with a 1.3% growth overall, driven by nearly 4% growth in hips and SET [27] - Global hips grew 2.4%, with U.S. growing 3.7% and international growing 1% [29] - Global knees grew 1.9%, with U.S. growing 0.2% and international growing 4.2% [30] Company Strategy and Development Direction - The company is focusing on three strategic priorities: people and culture, operational excellence, and innovation and diversification [12] - The integration of the Paragon 28 acquisition is a top priority, with the expectation of contributing approximately 270 basis points to sales growth in 2025 [10][23] - The company aims to achieve a 5% Vanguard weighted average market growth rate environment by the end of 2027 [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year organic constant currency revenue growth expectations of 3% to 5% [10] - The impact of tariffs is expected to be a headwind of $60 million to $80 million in 2025, with mitigation efforts already in place [38][47] - The second half of 2025 is anticipated to show higher organic constant currency growth due to easier comparisons and new product launches [37][56] Other Important Information - The company has made significant changes in leadership and sales strategies to bolster U.S. performance [12][27] - The introduction of new products, particularly in the hips and knees segments, is expected to drive growth [10][58] - The company is committed to reducing inventory days on hand, moving from over 400 days to approximately 370 days [15][34] Q&A Session Summary Question: Impact of tariffs on EPS and mitigation efforts - Management explained that the majority of production is in the U.S., which lowers exposure to tariffs, and outlined steps taken to mitigate impacts, including optimizing sourcing and moderating discretionary spending [46][47] Question: Clarification on growth expectations and new product impacts - Management indicated that Q1 growth of 2.3% constant currency, when adjusted for one less selling day, is close to mid-single-digit growth expectations, with confidence in new product introductions driving growth in the second half of 2025 [55][58] Question: Performance in ASC versus hospital channels - Management noted that over 20% of U.S. sales now come from the ASC environment, a significant increase from pre-COVID levels, and expressed confidence in continued growth in this area [96][97] Question: Pricing environment and future expectations - Management stated that pricing is expected to be flat for the year, with recent performance slightly better than initial guidance, and emphasized the stability of pricing in the near term [70][72]

Financial Data and Key Metrics Changes - In Q1 2025, Zimmer Biomet reported net sales of $1.909 billion, reflecting a 1.1% increase on a reported basis and a 2.3% increase excluding foreign currency impact [27] - Adjusted earnings per share (EPS) for the quarter was $1.81, down from $1.94 in the prior year, attributed to higher costs and investments [32] - The company generated $279 million in free cash flow, demonstrating robust growth compared to the previous year [26] Business Line Data and Key Metrics Changes - U.S. hips sales grew nearly 4%, while U.S. knees saw a modest growth of 0.2% [29] - The S.E.T. segment grew by 4.9%, with notable growth in CMFT and Sports categories [30] - International sales grew by 3.7%, driven by mid-single digit growth in knees and high-single digit growth in S.E.T. [28] Market Data and Key Metrics Changes - The U.S. market showed a 1.3% growth overall, with hips and S.E.T. driving performance [27] - Internationally, hips grew by 2.4%, with U.S. hips growing at 3.7% and international hips at 1% [29] - The company anticipates a full-year organic constant currency revenue growth of 3% to 5% for 2025 [10] Company Strategy and Development Direction - Zimmer Biomet is focusing on three strategic priorities: people and culture, operational excellence, and innovation and diversification [12] - The company aims to enhance its U.S. market performance through leadership changes and optimizing sales channels [14] - The recent acquisition of Paragon 28 is expected to contribute approximately 270 basis points to sales growth in 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the full-year guidance despite challenges such as tariffs and foreign exchange impacts [34] - The company is optimistic about new product launches and expects second-half growth to be higher than the first half due to favorable comparisons and new product uptake [35] - Management acknowledged the need for improved performance in the U.S. knee segment and is implementing strategies to enhance competitiveness [81] Other Important Information - The company reported a reduction in days on hand inventory from over 400 days in early 2024 to approximately 370 days [15] - The Paragon 28 acquisition was successfully integrated with minimal disruption, retaining key leadership and sales teams [110] Q&A Session Summary Question: Impact of tariffs on EPS and mitigation efforts - Management detailed steps taken to mitigate tariff impacts, including optimizing country of origin and sourcing adjustments, expecting a $60 million to $80 million headwind for 2025 [45][46] Question: Growth expectations and new product impacts - Management indicated confidence in achieving mid-single digit growth in the second half of 2025, driven by new product launches and improved execution [56][57] Question: Performance in ASC versus hospital channels - The company noted that over 20% of U.S. sales now come from the ASC environment, with expectations for continued growth in this area [94] Question: Pricing trends and future expectations - Management expects pricing to remain flat for 2025, with a stable environment compared to historical norms, despite previous fluctuations [68][69] Question: Clarification on the Paragon acquisition integration - The integration of Paragon 28 is progressing well, with all key personnel retained and ongoing product innovations maintained [110]